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Alzheimer’s diseaseAbstract Aim of the work: To study the neurobiochemical changes in patients with Alzheimer’s
disease (AD) by multivoxel 1H-MRS.
Materials and methods: Twenty-ﬁve patients with probable AD and 12 age- and sex-matched
normal controls were subjected to assessment of cognitive functions by the Mini Mental State
Examination (MMSE) and imaging with multivoxel 1H-MRS for measuring the NAA/Cho,
NAA/Cr, Cho/Cr, MI/NAA and MI/Cr ratios in the posterior cingulate gyrus (PCG) bilaterally.
Results: Patients with AD showed signiﬁcant decrease in NAA/Cho and NAA/Cr, signiﬁcant
increase in MI/NAA and MI/Cr and non-signiﬁcant increase in Cho/Cr ratios compared to control.
Also, the severity of cognitive impairment was signiﬁcantly associated with these changes. The
NAA/Cho ratio at a cut-off value 61.14 showed accuracy (94%), the NAA/Cr ratio at a cut-off
value 61.40 showed accuracy (97%), the Cho/Cr ratio at a cut-off value >1.29 showed accuracy
(85%), the MI/NAA ratio at a cut-off value >0.60 showed accuracy (98%), and the MI/Cr ratio
at a cut-off value >0.83 showed accuracy (97%).
496 R.E. Mohamed et al.Conclusion: The multi-voxels 1H-MRS of the PCG is sensitive to biochemical changes in AD. The
1H-MRS peak metabolite concentration ratios may be useful as markers for the progression of AD.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Alzheimer’s disease (AD) is themost common cause of dementia
in elderly people. It is a progressive neurodegenerative disease
that affects cortical and subcortical structures leading eventu-
ally to irreversible loss of neurons, particularly in the cortex
(1). In the early stages, the most common symptom is the difﬁ-
culty in remembering recent events, which is often mistakenly
thought to be age-related concerns (2). As the disease advances,
symptoms can include confusion, irritability, aggression, mood
swings, language problems and long-termmemory loss. Patients
oftenwithdraw from family and society.Gradually, bodily func-
tions are lost, ultimately leading to death (3).ADdevelops for an
unknown and variable amount of time before becoming fully
apparent, and it can progress undiagnosed for years (4). Patients
with AD rely on others for assistance, placing a great burden on
caregivers; with eventual social, psychological, physical and eco-
nomic effects of caregiver’s life (5). In developed countries, AD
is one of the most costly diseases to the society (6).
Neuroimaging techniques may have an important role in
the clinical evaluation of AD for early diagnosis, differential
diagnosis and monitoring of disease activity. The proton mag-
netic resonance spectroscopy (1H-MRS) is a non-invasive
imaging modality for biomarkers in AD, which is important
for both early diagnosis and evaluating treatment effects. This
imaging technique may provide a window into the biochemical
changes associated with the loss of neuronal integrity and
other neurodegenerative pathology that involves the brain be-
fore the manifestations of cognitive impairment in patients
who are at risk for AD (7).
The neural network correlates of consciousness are un-
evenly distributed neuronal aggregates involved in conscious
awareness. A critical node in this network is the posterior cin-
gulate gyrus (PCG), which is the backmost part of the cingu-
late cortex lying behind the anterior cingulate gyrus (ACG),
the upper part of the limbic lobe. The cingulate cortex is made
up of an area around the midline of the brain. The PCG is
commonly affected by neurodegenerative disease. Reduced
metabolism in the PCG is an early sign of AD and is frequently
present before clinical diagnosis (8). Furthermore, 1H-MRS of
the PCG was more sensitive to the biochemical changes in pa-
tients with mild cognitive impairment (MCI) and AD than 1H-
MRS of other neocortical regions in the brain (9).
With the aim of further contributing to the knowledge of the
in vivo neurobiochemical changes of normal aging and AD, we
carried out the present study performing multi-voxel 1H-MRS
on the PCG of patients with AD and age-matched controls.2. Materials and methods
2.1. Study participants
This study, performed from March 2012 to August 2013, in-
cluded 25 patients (15 males and 10 females; age ranged from64 to 85 years; mean 72.3 ± 10.4 years) referred to the Neurol-
ogy Department of our institution fulﬁlling the National Insti-
tute of Neurological and Communicative Disorders and
Stroke and the Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) criteria for probable AD
(10). The Mini Mental State Examination (MMSE) test was
used to evaluate the degree of cognitive impairment (11).
Twelve normal subjects (8 males, 4 females; age ranged from
51 to 92 years; mean 71.2 ± 11.4 years) were selected amongst
relatives or caregivers of the studied patients and served as the
control group. All of them had a clinical history negative for
neurological disease, mental disorder, head trauma or other
relevant pathologies such as stroke, and scored >26 on
MMSE. Illiterate subjects, subjects with physical problems
interfering with test interpretation (for example, physically un-
able to hear or read instructions properly), or subjects with
motor deﬁcits affecting writing and drawing skills were ruled
out. Additionally, we excluded patients with any metabolic ill-
nesses that affect the cerebral peak metabolite concentration
ratios such as diabetes mellitus as it was proved that myo-ino-
sitol/creatine (MI/Cr) ratio increases in the brains of patients
with diabetes mellitus (12). Neither patients nor controls were
taking any medications at the time of examinations. An in-
formed consent from subjects enrolled in the study and/or their
caregivers was obtained. An ofﬁcial permission to carry out
the study was also obtained from the responsible authorities.
The MMSE is a brief 30-point questionnaire test that is
commonly used to screen for dementia. It is also used to esti-
mate the severity and follow the course of cognitive impair-
ment. In the MMSE, any score greater than or equal to 26
points (out of 30) indicates a normal cognition. Below this,
scores can indicate severe (69 points), moderate (10–18 points)
or mild (19–25 points) cognitive impairment (13). So, patients
were further divided into three subgroups according to their
points on the MMSE into mild, moderate and severe AD.
2.2. Imaging procedures
Study participants were examined initially with MRI and then
with multivoxel 1H-MRS by using 1.5-Tesla MR unit, which
had a spectroscopy capability (Signa Horizon SR 120; General
Electric Medical Systems, Milwaukee, WI, USA) using a stan-
dard quadrature head coil (28 cm quadrature birdcage resona-
tor). The MRI studies comprised the following sequences:
multiplanar axial T1-weighted fast spin-echo (T1WFSE) with
repetition time/echo time/number of excitations (TR/TE/
NEX) of 500/14/2, multiplanar axial T2-weighted fast spin-
echo (T2WFSE) with TR/TE/NEX of 4000/126/2, and axial
ﬂuid-attenuated inversion recovery (FLAIR) with TR/TE/
NEX of 8000/142/1 and inversion time (TI) of 2200 ms (ms).
2.3. 1H-MRS protocol
The 1H-MRS was performed by using two-dimensional
multivoxel long-echo (TE of 144 ms) point-resolved spatially
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trations of metabolites with biological importance including:
N-acetylaspartate (NAA), choline (Cho), creatine (Cr), lactate
(Lac) and myo-inositol (MI). The PCG was examined bilater-
ally in both patients and control groups by using a spin-echo
(SE) mode sequence. In all patients, the obtained spectra were
displayed as grids of localised voxels with nominal size of
10 · 10 · 10 mm, which were overlaid on the conventional
MR images (either axial T2-weighted images or axial FLAIR
images).
The localised voxels of interest (VOIs) were located in the
posterior cingulate region in which they were placed below
the cingulate sulci and above the parieto-occipital sulci, cover-
ing the PCG and inferior precunei bilaterally as regions of
interest (ROIs). Water resonance suppression was optimally
achieved by using the chemical shift selective water suppres-
sion (CHESS) technique. In all patients, the used parameters
were TR 1000, TE 144 and 35 ms, FOV 24 cm, 18 · 18 phase
encoding matrices, 1.0 cm section thickness, 2500 Hz spectral
width and 2048 data points. The MRS scan was initiated if
the line width reported by the pre-scan process was less than
8 Hz. The MR spectra obtained with a long TE of 144 ms
and an additional short TE of 35 ms were utilised to conﬁrm
the phase inversion associated with J-coupled metabolites of
lactate, and amino acids, but not of lipids, which may be help-
ful to discriminate lactate or amino acid signals from lipid sig-
nals. The acquisition time for each sequence was 5 min and
54 s. The Off-line spectral post-processing was carried out by
using a semi-automated software (Functool, Version 2.33,
GE Medical Systems, Milwaukee, WI, USA).
The main metabolite resonances were limited to 2.02 ppm
(ppm) for NAA, 3.02 ppm for Cr, 3.20 ppm for Cho and
3.56 ppm for MI. As a result of difﬁculties in the calculation
of the absolute metabolite concentrations, their relative con-
centration ratios were assessed by using the method of relative
quantiﬁcation with calculation of peak ratios of the NAA/Cr,
NAA/Cho, Cho/Cr, MI/NAA and MI/Cr in each PCG sepa-
rately in all patients and controls. The means of these peak ra-
tios were then calculated in each of the three subgroups of
patients and compared with those of the control group.
2.4. Statistical analysis
The data were collected and revised. Quantitative data were
expressed as mean ± standard deviation (SD). The Receiver
Operating Characteristic (ROC) curves for the mean peak
metabolite concentration ratios were obtained and plotted by
using a maximum likelihood curve-ﬁtting algorithm. Relative
diagnostic accuracy was estimated for each ratio by using theTable 1 Age, sex and MMSE in patients versus controls.
Parameter Patients (n= 25)
Age (in years) Range 64–85
Mean ± SD 72.3 ± 10.4
Sex Female; n 10
Male; n 15
MMSE Range 7–22
Mean ± SD 14.7 ± 5.4
MMSE, Mini Mental State Examination; n, number.
* Signiﬁcant.individual area under the ROC curve to identify the optimal
cut-off values. The student t-test and chi-square test were used
for comparison between two groups and the analysis of vari-
ance (ANOVA) test was used for correlation of the data.
The SPSS for Windows version 18.0 software package (SPSS
Inc., Chicago, IL) was used for statistical data analysis. P-va-
lue <0.05 was considered statistically signiﬁcant.
3. Results
This study included 25 patients with AD and 12 age- and sex-
matched normal controls. The MMSE score in AD patients
ranged from 8 to 22 with a mean of 14.7 ± 5.4 that was signif-
icantly lower than that of controls (P< 0.001); (Table 1). The
duration of dementia ranged from 12 to 96 months (mean
60 ± 12.5 months).
The peak metabolite concentration ratios were bilaterally
measured in the PCG of all study participants. Patients with
AD showed signiﬁcant decrease in the mean peak metabolite
concentration ratios of both NAA/Cho (P< 0.001) and
NAA/Cr (P< 0.001). Also, they showed a signiﬁcant increase
in the mean peak metabolite concentration ratios of MI/NAA
(P< 0.001) and MI/Cr (P< 0.001). Although, the mean con-
centration ratio of Cho/Cr increased in patients with AD com-
pared to that of the control group, this difference was not
signiﬁcant (P= 0.91); (Table 2).
The relationship between the means of the peak metabolite
ratios and the degree of cognitive impairment evaluated by the
MMSE was assessed. Severity of cognitive impairment in pa-
tients with AD was signiﬁcantly associated with decreased
NAA/Cho and NAA/Cr ratios (P< 0.001). On the other
hand, it was signiﬁcantly associated with increased MI/NAA
and MI/Cr ratios (P< 0.001). However, a non signiﬁcant in-
crease in the mean Cho/Cr ratio was observed amongst differ-
ent stages of AD in the group of patients (P= 0.60); (Table 3).
Table 4 and Figs. 1 and 2 demonstrated the results of the
ROC curve analysis of the studied peak metabolite concentra-
tion ratios in patients with AD and their accuracy in distin-
guishing such patients from cognitively normal elderly. The
NAA/Cho ratio at a cut-off value 61.14 showed sensitivity
(96%), speciﬁcity (91.7%), PPV (96%), NPV (91.7%) and
accuracy (94%). The NAA/Cr ratio at a cut-off value 61.40
showed sensitivity (100%), speciﬁcity (92%), PPV (96.2%),
NPV (100%) and accuracy (97%). The Cho/Cr ratio at a
cut-off value >1.29 showed sensitivity (84%), speciﬁcity
(90.9%), PPV (95.5%), NPV (73.3%) and accuracy (85%).
The MI/NAA ratio at a cut-off value >0.60 showed sensitivity
(100%), speciﬁcity (91.9%), PPV (96.2%), NPV (100%) and
accuracy (98%). The MI/Cr ratio at a cut-off value >0.83Controls (n= 12) Test value P-value
51–92 t= 0.292 0.772
71.2 ± 11.4
4 X2 = 0.001 0.976
8
26–30 t= 8.933 <0.001*
28.9 ± 1.25
Table 2 The mean metabolite concentration ratios in patients versus control.
Metabolite ratio Patients (n= 25) Controls (n= 12) T-test
Mean ± SD Mean ± SD t P-value
NAA/Cho 1.02 ± 0.22 1.46 ± 0.29 4.71 <0.001*
NAA/Cr 1.05 ± 0.26 1.74 ± 0.44 5.09 <0.001*
Cho/Cr 1.29 ± 0.20 1.15 ± 0.25 1.77 0.91
MI/NAA 0.80 ± 0.21 0.46 ± 0.12 6.30 <0.001*
MI/Cr 1.04 ± 0.16 0.53 ± 0.28 5.38 <0.001*
* Signiﬁcant <0.05.
Table 3 Relationship between the mean metabolite concentration ratios and the degree of cognitive impairment assessed by the
MMSE.
Metabolite ratio Mini Mental State Examination (mean ± SD) ANOVA
Mild (n= 8) Moderate (n= 10) Severe (n= 7) F P-value
NAA/Cho 1.23 ± 0.08 1.02 ± 0.12 0.77 ± 0.16 26.34 <0.001*
NAA/Cr 1.25 ± 0.14 1.09 ± 0.18 0.75 ± 0.18 17.25 <0.001*
Cho/Cr 1.25 ± 0.10 1.27 ± 0.17 1.35 ± 0.31 0.52 0.60
MI/NAA 0.69 ± 0.07 0.72 ± 0.13 1.06 ± 0.20 17.11 <0.001*
MI/Cr 0.91 ± 0.05 1.04 ± 0.09 1.19 ± 0.21 8.89 <0.001*
* Signiﬁcant <0.05.
Table 4 Sensitivity, speciﬁcity, predictive values and accuracy of the metabolite ratios in patients with AD (n= 25).
Metabolite ratio Cut-oﬀ Sensitivity % Speciﬁcity % PPV % NPV % Accuracy %
NAA/Cho 61.14 96.0 91.7 96.0 91.7 94
NAA/Cr 61.40 100.0 92.0 96.2 100.0 97
Cho/Cr >1.29 84.0 90.9 95.5 73.3 85
MI/NAA >0.60 100.0 91.9 96.2 100.0 98
MI/Cr >0.83 100.0 91.6 96.2 100.0 97
PPV, positive predictive value; NPV, negative predictive value.
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NPV (100%) and accuracy (97%).
3.1. Cases
The ﬁgures (from 3 to 6) demonstrate a sample of selected
cases of our study; in which each ﬁgure outlines only one case
including: a normal control (Fig. 3), a case with mild AD
(Fig. 4), a case with moderate AD (Fig. 5) and a case with ad-
vanced AD (Fig. 6).
4. Discussion
Alzheimer disease is an acquired disorder of cognitive and
behavioural impairment that markedly interferes with social
and occupational functioning (14). It is an incurable disease
having a long and progressive course with major public health
problems (15). The increasing prevalence rate of AD and the
upcoming new speciﬁc therapeutic possibilities lead to the need
of earlier and more accurate diagnosis of the disease (7).
Amongst diagnostic imaging modalities, the 1H-MRS is con-
sidered as a valuable tool for early diagnosis of AD, as it al-
lows, in a non-invasive manner, determination of regionalconcentration ratios of a number of critical neurochemicals
in both normal and pathologic nervous tissues in vivo (1).
The NAA is an amino acid present primarily within neu-
rons in the central nervous system as well as in dendrites and
axons. It is an acetyl donor in lipid synthesis, which is present
in neurons and is actively involved in myelin synthesis. There-
fore, it is a very speciﬁc marker for viable neurons, axons and
dendrites. The diagnostic utility of NAA is based on its ability
to quantify neuronal injury or loss on a regional basis; there-
fore it is widely used as a marker of neuronal density and as
an in vivo marker of neurometabolic ﬁtness. Reduced NAA
concentration in the PCG has been described in patients with
AD using 1H-MRS (9). Moreover, Cr is an important indica-
tor of the energy metabolism and is used as an internal refer-
ence to calculate the concentration of the other metabolites.
In addition, Cho is generally used as a marker of cellular
density and membrane turnover, so it reﬂects the damaged
cholinergic neurons in AD. Furthermore, MI, which is a
sugar-alcohol, is primarily located in glial cells and often inter-
preted as a marker of gliosis and glial cell numbers, as it exists
in a considerably higher concentration within glial cells (16).
The PCG is a part of the limbic system involved in memory
retrieval and evaluation of information (17). Abnormalities
within the PCG are associated with the earliest pathologic
Fig. 1 (A–E) Demonstrates the NAA/Cho (A), NAA/Cr (B), Cho/Cr (C), MI/NAA (D) and MI/Cr (E) values, which were obtained
from patients and controls.
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ces. The hippocampus and PCG are considered as the earliest
structures to show hypoperfusion or hypometabolism. Fur-
thermore, degeneration of the hippocampus and PCG can be
used to follow the progression of the degenerative process
and allows for a spectroscopic staging of AD (18).In the current study, we used multivoxel 1H-MRS to study
changes in the metabolite concentration ratios of the NAA/
Cho, NAA/Cr, Cho/Cr, MI/NAA and MI/Cr of the PCG in
patients with AD and age- matched normal controls aiming
to study the neurochemical pattern of normal aging and AD.
As in previous studies (7,9,18,19), although done on different
Fig. 2 Demonstrates the ROC curve analysis of peak metabolite
concentration ratios of NAA/Cho (at cut-off value 61.14 with
sensitivity 96% and speciﬁcity 91.7%), NAA/Cr (at a cut-off value
61.40 with sensitivity 100% and speciﬁcity 92%), Cho/Cr (at a
cut-off value >1.29 with sensitivity 84% and speciﬁcity 90.9%),
MI/NAA (at a cut-off value >0.60 with sensitivity 100% and
speciﬁcity 91.9%), and MI/Cr (at a cut-off value >0.83 with
sensitivity 100% and speciﬁcity 91.6%) between patients and
controls.
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metabolite concentration ratios of NAA/Cho (P< 0.001)
and NAA/Cr (P< 0.001) in the PCG of patients with AD,
whilst the mean metabolite concentration ratios of MI/NAA
and MI/Cr signiﬁcantly increased (P< 0.001). Also, we found
non-signiﬁcant increase of the mean Cho/Cr ratio in patients
with AD compared to normal control (P= 0.91). This latter
ﬁnding was also observed by Kantarci (20) who suggests that
Cho/Cr elevation might be a preclinical marker for AD in el-
derly. The reduction of NAA observed in patients with AD
could be attributed to neuronal loss or dysfunction, and the
elevation of MI to gliosis (19). In addition, Liu et al. (21), ob-
served a reduction in NAA/Cr ratio in patients with MCI
when compared to normal control. Furthermore, Zhoua
et al. (18), observed increased MI/Cr peak intensity ratio, with
decreased NAA/Cr, in patients with early probable AD but
they did not ﬁnd changes in the Cho/Cr ratio. Also, Kizu
et al. (22), reported non-signiﬁcant changes in Cho/Cr ratios
in the PCG in AD patients. The rise in grey matter Cho levels
has been associated with decline in memory function and re-
gional cerebral metabolism (23). However, Block et al. (24),
found no signiﬁcant changes in the Cho resonance in subjects
with AD. Moreover, Loos et al. (16), reported that a fall in
NAA/Cr, with an increase in MI/Cr, favours the diagnosis
of AD. Furthermore, Lim et al. [25], concluded that both the
decreased NAA/Cr of the PCG and the increased MI/Cr of
the ACG may reﬂect biochemical changes in AD according
to the posterior-dominant progression of AD pathology. How-
ever, Menezes et al. (26), who studied changes in the metabo-
lite concentration ratios in the hippocampus of patients with
MCI and early mild AD as well as normal aging individuals,
concluded that the ratio value of metabolites NAA/Cr, MI/
Cr, Cho/Cr and MI/NAA did not show any signiﬁcant differ-
ences between controls versus MCI or mild AD patients.
The MMSE is a useful and widely used clinical screening
tool for dementia. It is one of the criteria recommended by
the National Institute for Clinical Excellence in following clin-
ical status after treatment of AD with cholinesterase inhibitors.
The association between MMSE score and MI elevation in theposterior cingulate region of the brain is considered as a rela-
tively speciﬁc marker for AD. Additionally, the presence of a
correlation between NAA/Cr and MMSE in the AD is a key
ﬁnding in its diagnosis (27).
In the present study, we recognised that the mean MMSE
score in the group of patients signiﬁcantly reduced compared
to that of the control group (P< 0.001). Moreover, we classi-
ﬁed the severity of AD in the group of patients based on
MMSE into mild, moderate and severe, and observed that
the severity of cognitive impairment in patients with AD was
signiﬁcantly (P< 0.001) associated with decreased NAA/
Cho and NAA/Cr mean metabolite ratios as well as increased
MI/NAA and MI/Cr mean metabolite ratios in the PCG. This
is in harmony with the results of prior studies (18,20,25,28)
who stated that, the total MMSE scores obtained for MCI
and AD signiﬁcantly decreased compared to the control group
(P< 0.05). Also, they observed a signiﬁcant association be-
tween NAA/Cr and MI/NAA ratios in the PCG and the
MMSE in patients with AD and they depicted that the pro-
gressive decrease of NAA in such patients runs parallel with
the decline in the MMSE scores. Additionally, we recognised
a non-signiﬁcant increase in the mean concentration ratio of
Cho/Cr with increased severity of cognitive impairment in
AD patients (P= 0.60). This is in accordance with Modrego
et al. (29), who observed that the increased metabolite concen-
tration ratio of Cho/Cr in different stages of AD in the poster-
ior cingulate area was statistically not signiﬁcant.
1H-MRS is sensitive to biochemical changes during the
pathologic progression of AD before there is a signiﬁcant loss
of neuronal integrity. In addition, it is useful for predicting and
monitoring different pathological stages in the course of AD
(9). Currently, we used ROC curve analysis of the studied
metabolite concentration ratios in the PCG of patients with
AD to evaluate their accuracy in distinguishing such patients
from cognitively normal elderly. We observed that MI/NAA,
NAA/Cr and MI/Cr metabolite concentration ratios had high-
est sensitivity, speciﬁcity and accuracy in prediction and eval-
uation of patients with AD. Our results showed that the NAA/
Cho ratio at a cut-off value 61.14 had sensitivity (96%), spec-
iﬁcity (91.7%), PPV (96%), NPV (91.7%) and accuracy
(94%). Moreover, NAA/Cr ratio at a cut-off value 61.40
showed sensitivity (100%), speciﬁcity (92%), PPV (96.2%),
NPV (100%) and accuracy (97%). The Cho/Cr ratio at a
cut-off value >1.29 showed sensitivity (84%), speciﬁcity
(90.9%), PPV (95.5%), NPV (73.3%) and accuracy (85%).
Additionally, the MI/NAA ratio at a cut-off value >0.60 de-
picted sensitivity (100%), speciﬁcity (91.9%), PPV (96.2%),
NPV (100%) and accuracy (98%). Finally, the MI/Cr ratio
at a cut-off value >0.83 showed sensitivity (100%), speciﬁcity
(91.6%), PPV (96.2%), NPV (100%) and accuracy (97%).
Kantarci et al. (30), demonstrated that NAA/Cr measured
from the PCG added predictive value for conversion to demen-
tia. Furthermore, Modrego et al. (29), demonstrated that ROC
curve analysis for NAA/Cr < 1.61 predicted conversion of
MCI into AD with 100% sensitivity, 75% speciﬁcity, PPV of
83% and NPV of 100% with area under the curve of 0.91. Sim-
ilarly, Fayed et al. (31), showed that NAA/Cr < 1.40 in the
PCG predicted conversion of MCI to probable AD with sensi-
tivity of 82% and speciﬁcity of 72% with area under the curve
of 0.82. Finally, Modrego et al. (32), showed that NAA/
Cr < 1.43 in posteromedial parietal cortex predicted conver-
sion to probable AD with 74% sensitivity and 84% speciﬁcity
Fig. 3 (A–F) Demonstrates a sixty-ﬁve year old healthy elderly
male volunteer with MMSE score of 28. The 1H-MRS multivoxel
picture (A), and MRS spectrum of the right (B) and left (C)
posterior cingulate gyri at a long TE of 144 ms, in addition to 1H-
MRS multivoxel picture (D), and MRS spectrum of the right (E)
and left (F) posterior cingulate gyri at a short TE of 35 ms reveal
normally average NAA/Cr, NAA/Cho, Cho/Cr, Lac/NAA and
MI/NAA peak metabolite concentration ratios of both posterior
cingulate gyri. These ratios are (NAA/Cr = 1.78, NAA/Cho =
1.30, Cho/Cr = 1.36, MI/NAA= 0.35 and MI/Cr = 0.57) in the
right PCG (B and E) and (NAA/Cr = 1.75, NAA/Cho = 1.5,
Cho/Cr = 1.17, MI/NAA= 0.38 and MI/Cr = 0.56) in the left
PCG (C and F).
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surements could predict cognitive decline and monitor disease
activity in patients with clinically established AD [20]. More-
over, MI/NAA and NAA/Cr ratios can be considered as early
predictors for prodromal AD in people with MCI (9).
We thought that our study might provide an important
close idea about the AD and the changes of brain metabolite
concentration ratios, which might help for early diagnosis of
the disease in a preclinical stage and hence early management.
We obtained the MR spectra at two different echo times, a
long TE of 144 ms and an additional short TE of 35 ms which
were used to prove the phase inversion associated with J-cou-
pled metabolites of lactate and amino acids, but not of lipids in
order to distinguish lactate or amino acid signals from lipid
signals. Additionally, we considered the use of PCG for place-
ment of 1H-MRS voxels to involve PCG and inferior precunei
bilaterally, as a strengthening point of our study. The PCG is a
limbic cortical region that is affected relatively early in the
pathologic progression of AD. Furthermore, the midline loca-
tion of the posterior cingulate voxels allows high quality spec-
tra and reproducible voxel placement with easy evaluation of
bilateral posterior cingulate gyri in the same patient (18), as
well as appropriate evaluation of the alterations in the metab-
olite concentration ratios at different stages of the disease.
Additionally, we used the ROC curve analysis of the studied
different metabolite concentration ratios in the posterior cin-
gulate gyri of patients with AD and we evaluated the optimal
cut-off values of these ratios with best sensitivity, speciﬁcity,
predictive values and accuracy in assessment of the severity
of the disease and prediction of progress of cognitive impair-
ment with better differentiation between patients with AD
and cognitively normal elderly.
Regrettably we faced some limitations. Although, the loca-
tion of the posterior cingulate voxel was relatively free of air-
bone-brain interface susceptibility problems, we considered the
un-examination of the anteromedial temporal lobe, including
hippocampus and entorhinal cortex as a limitation. However,
we were incapable to constantly acquire technically satisfac-
tory quality spectra from this region as a result of the proxim-
ity of magnetic susceptibility artifacts created by the tissue-air
interface near the petrous bone. Moreover, obtaining spectra
from a voxel small enough to sample the anteromedial tempo-
ral lobe structures without partial voluming could not be
achieved. Thus, the most technically robust and functionally
appropriate regions to study are the posterior cingulate gyri
(9). Also, previous studies (18,25) observed that the posterior
cingulate voxel was better than that in other regions in the
brain, such as superior temporal lobe and medial occipital
lobe. Moreover, the small number of patients in the current
study was another limitation. So, further extended studies on
a larger number of patients utilising a standardised enrolment
and diagnosis criteria, data acquisition methods, should be
conducted to set up normative values.
In summary, AD is associated with dysfunction of
networks implicated in human amnesia. The multi-voxels
1H-MRS at 1.5 Tesla of the PCG is sensitive to the biochem-
ical changes in AD. Therefore, this non-invasive technique
has a great potential in becoming an adjunct to the clinical
evaluation and management of such disease. The 1H-MRS
peak metabolite concentration ratios may be useful as markers
for the progression of AD. In view of our study, we observed
that MI/NAA (at cut-off value >0.06), NAA/Cr (at cut-off
Fig. 4 (A–D) Demonstrates a sixty-seven year old female patient
with mild degree of AD and her MMSE score is 20. The MRS
spectrum of the right (A) and left (B) posterior cingulate gyri at a
long TE of 144 ms, in addition to MRS spectrum of the right (C)
and left (D) posterior cingulate gyri at a short TE of 35 ms reveal
signiﬁcant reduction in the NAA/Cr, NAA/Cho peak metabolite
concentration ratios of both posterior cingulate gyri. Additionally,
there is signiﬁcant increase in the MI/NAA and MI/Cr as well as
non signiﬁcant increase in the Cho/Cr peak metabolite concen-
tration ratios of both posterior cingulate gyri. These ratios are
(NAA/Cr = 1.39, NAA/Cho = 1.19, Cho/Cr = 1.17, MI/
NAA= 0.58 and MI/Cr = 0.86) in the right PCG (A and C)
and (NAA/Cr = 1.37, NAA/Cho = 0.96 and Cho/Cr = 1.18,
MI/NAA= 0.58 and MI/Cr = 0.86) in the left PCG (B and D).
Fig. 5 (A–F) Represents a seventy-eight year old male patient
with moderate degree of AD and his MMSE score is 12. The 1H-
MRS multivoxel picture (A) as well as MRS spectrum of the right
(B) and left (C) posterior cingulate gyri at a long TE of 144 ms, in
addition to 1H-MRS multivoxel picture (D) as well as 1H-MRS
spectrum of the right (E) and left (F) posterior cingulate gyri at a
short TE of 35 ms reveal signiﬁcant reduction in the NAA/Cr,
NAA/Cho peak metabolite concentration ratios of both posterior
cingulate gyri. Additionally, there is signiﬁcant increase in the MI/
NAA and MI/Cr as well as non signiﬁcant increase in the Cho/ Cr
peak metabolite concentration ratios of both posterior cingulate
gyri. These ratios are (NAA/Cr = 1.08, NAA/Cho = 0.80, Cho/
Cr = 1.34, MI/ NAA= 0.62 and MI/ Cr = 0.84) in the right
PCG (B and E) and (NAA/Cr = 1.05, NAA/Cho = 0.972 and
Cho/Cr = 1.083, MI/ NAA= 0.69 and MI/Cr = 0.80) in the left
PCG (C and F).
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Fig. 6 (A–F) Demonstrates a seventy year old male patient with
severe degree of AD and his MMSE score is 8. The 1H-MRS
multivoxel picture (A), and MRS spectrum of the right (B) and left
(C) posterior cingulate gyri at a long TE of 144 ms, in addition to
1H-MRS multivoxel picture (D), and MRS spectrum of the right
(E) and left (F) posterior cingulate gyri at a short TE of 35 ms
reveal signiﬁcant reduction in the NAA/Cr, NAA/Cho peak
metabolite concentration ratios of both posterior cingulate gyri.
Additionally, there is signiﬁcant increase in the MI/NAA and MI/
Cr as well as non signiﬁcant increase in the Cho/Cr peak
metabolite concentration ratios of both posterior cingulate gyri.
These ratios are (NAA/Cr = 0.9, NAA/Cho = 0.61, Cho/
Cr = 1.5, MI/NAA= 0.74 and MI/Cr = 1.03) in the right PCG
(B and E) and (NAA/Cr = 0.92, NAA/Cho = 0.50, Cho/
Cr = 1.83, MI/NAA= 0.77 and MI/Cr = 1.04) in the left PCG
(C and F).
In vivo neurobiochemical changes of the posterior cingulate gyrus 503value 61.40) and MI/Cr (at cut-off value >0.83), had highest
sensitivity, speciﬁcity and accuracy in prediction and evalua-
tion of patients with AD. Also, we observed that the severity
of cognitive impairment in patients with AD was signiﬁcantly
(P< 0.001) associated with decreased NAA/Cho and NAA/
Cr peak metabolite concentration ratios as well as increased
MI/NAA and MI/Cr peak metabolite concentration ratios in
the PCG of patients with AD.Conﬂict of interest
None.
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